Loading…
Reported covered position: LA,Rep Capps 2001-05 PSM, Sen HELP Comm 2007-10 LD, Sen Dodd 2010 DAS for Leg, HHS, 2011-13 Counselor, HHS, 2013-14 Dep Commissioner for Policy, FDA 2015-17
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
Client: MEDICINES360 · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
Client: MEDICINES360 · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2026 · third_quarter · Q3
COVID-19 response legislation:
Support for non-profit pharmaceutical manufacturers
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Source: Senate LDA
| NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS |
| 13 |
| 2020–2023 |
| BRAEBURN INC. | 3 | 2018 |
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
Client: MEDICINES360 · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
Client: MEDICINES360 · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
To prevent across-the-board direct spending cuts, and for other purposes.
Client: CALIFORNIA ASSOCIATION OF PUBLIC HOSPITALS AND HEALTH SYSTEMS · Firm: WAXMAN STRATEGIES
Reversing policies that harm CAPH and its members through support of H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
Client: MEDICINES360 · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
Client: MEDICINES360 · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
Client: MEDICINES360 · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Further Consolidated Appropriations Act, 2020
Client: CAMPAIGN FOR TOBACCO FREE KIDS · Firm: WAXMAN STRATEGIES
H.R. 2339, HR 1865 - Issues related to tobacco, e-cigarettes and public health.
Further Consolidated Appropriations Act, 2020
Client: CAMPAIGN FOR TOBACCO FREE KIDS · Firm: WAXMAN STRATEGIES
H.R. 2339, HR 1865 - Issues related to tobacco, e-cigarettes and public health.
Further Consolidated Appropriations Act, 2020
Client: CAMPAIGN FOR TOBACCO FREE KIDS · Firm: WAXMAN STRATEGIES
H.R. 2339, HR 1865 - Issues related to tobacco, e-cigarettes and public health.
Further Consolidated Appropriations Act, 2020
Client: CAMPAIGN FOR TOBACCO FREE KIDS · Firm: WAXMAN STRATEGIES
H.R. 2339, HR 1865 - Issues related to tobacco, e-cigarettes and public health.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020
Client: CAMPAIGN FOR TOBACCO FREE KIDS · Firm: WAXMAN STRATEGIES
H.R. 2339, HR 1865 - Issues related to tobacco, e-cigarettes and public health.
Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020
Client: CAMPAIGN FOR TOBACCO FREE KIDS · Firm: WAXMAN STRATEGIES
H.R. 2339, HR 1865 - Issues related to tobacco, e-cigarettes and public health.
Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020
Client: CAMPAIGN FOR TOBACCO FREE KIDS · Firm: WAXMAN STRATEGIES
H.R. 2339, HR 1865 - Issues related to tobacco, e-cigarettes and public health.
Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020
Client: CAMPAIGN FOR TOBACCO FREE KIDS · Firm: WAXMAN STRATEGIES
H.R. 2339, HR 1865 - Issues related to tobacco, e-cigarettes and public health.
Elijah E. Cummings Lower Drug Costs Now Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Families First Coronavirus Response Act
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Families First Coronavirus Response Act
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Families First Coronavirus Response Act
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Families First Coronavirus Response Act
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Prescription Drug Pricing Reduction Act of 2019
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Prescription Drug Pricing Reduction Act of 2019
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Prescription Drug Pricing Reduction Act of 2019
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Prescription Drug Pricing Reduction Act of 2019
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act; S. 2543 - The Prescription Drug Pricing Reduction Act.
Reducing High Risk to Veterans and Veterans Services Act of 2020
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Reducing High Risk to Veterans and Veterans Services Act of 2020
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Reducing High Risk to Veterans and Veterans Services Act of 2020
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Reducing High Risk to Veterans and Veterans Services Act of 2020
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
COVID-19 response legislation: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748/S.3458, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Air Carrier Access Amendments Act of 2019
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
Air Carrier Access Amendments Act (H.R. 1549, S. 669) - lobbied several offices to cosponsor legislation, coordinated with lead House and Senate sponsors on strategy
Further Consolidated Appropriations Act, 2020
Client: CAMPAIGN FOR TOBACCO FREE KIDS · Firm: WAXMAN STRATEGIES
H.R. 2339, HR 1865 - Issues related to tobacco, e-cigarettes and public health.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020
Client: CAMPAIGN FOR TOBACCO FREE KIDS · Firm: WAXMAN STRATEGIES
H.R. 2339, HR 1865 - Issues related to tobacco, e-cigarettes and public health.
Elijah E. Cummings Lower Drug Costs Now Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Air Carrier Access Amendments Act of 2019
Client: CHRISTOPHER AND DANA REEVE FOUNDATION · Firm: WAXMAN STRATEGIES
Air Carrier Access Amendments Act (H.R. 1549, S. 669) - lobbied several offices to cosponsor legislation, coordinated with lead House and Senate sponsors on strategy
To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client: BRAEBURN INC. · Firm: WAXMAN STRATEGIES
Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2017 and HR 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client: BRAEBURN INC. · Firm: WAXMAN STRATEGIES
Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2017 and HR 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client: BRAEBURN INC. · Firm: WAXMAN STRATEGIES
Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2017 and HR 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Issues impacting the 340B drug discount program; SERV Communities Act HR 6071
Issues impacting the 340B drug discount program; SERV Communities Act HR 6071
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Hatch-Waxman Integrity Act of 2018
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; Hatch-Waxman Integrity Act, S. 3738; S.974 - Creating and Restoring Equal Access to Equivalent Samples Act
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client: BRAEBURN INC. · Firm: WAXMAN STRATEGIES
Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2017 and HR 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client: BRAEBURN INC. · Firm: WAXMAN STRATEGIES
Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2017 and HR 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client: BRAEBURN INC. · Firm: WAXMAN STRATEGIES
Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2017 and HR 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; Hatch-Waxman Integrity Act, S. 3738; S.974 - Creating and Restoring Equal Access to Equivalent Samples Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2026 · third_quarter · Q3
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2026 · third_quarter · Q3
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; appropriations for 340B program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2026 · first_quarter · 1T
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2026 · second_quarter · Q2
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2026 · second_quarter · Q2
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Support for non-profit pharmaceutical manufacturers
COVID-19 response legislation:
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2026 · second_quarter · Q2
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; appropriations for 340B program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2026 · first_quarter · Q1
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2026 · first_quarter · Q1
COVID-19 response legislation:
Support for non-profit pharmaceutical manufacturers
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2026 · first_quarter · 1A
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; appropriations for 340B program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2026 · first_quarter · Q1
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2026 · first_quarter · Q1
Issues affecting the 340B drug pricing program, drug prices, and health care costs
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2025 · fourth_quarter · Q4
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2025 · fourth_quarter · Q4
Support for non-profit pharmaceutical manufacturers
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
COVID-19 response legislation:
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2025 · fourth_quarter · Q4
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2025 · fourth_quarter · Q4
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2025 · third_quarter · Q3
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2025 · third_quarter · Q3
Support for non-profit pharmaceutical manufacturers
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
COVID-19 response legislation:
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2025 · third_quarter · Q3
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2025 · third_quarter · Q3
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2025 · second_quarter · Q2
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2025 · second_quarter · Q2
Support for non-profit pharmaceutical manufacturers
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
COVID-19 response legislation:
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2025 · second_quarter · Q2
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2025 · second_quarter · Q2
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2025 · first_quarter · Q1
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2025 · first_quarter · Q1
Support for non-profit pharmaceutical manufacturers
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
COVID-19 response legislation:
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2025 · first_quarter · Q1
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2025 · first_quarter · Q1
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2024 · fourth_quarter · Q4
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2024 · fourth_quarter · Q4
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
COVID-19 response legislation
Support for non-profit pharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2024 · fourth_quarter · Q4
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2024 · fourth_quarter · Q4
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2024 · third_quarter · Q3
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2024 · third_quarter · Q3
Support for non-profit pharmaceutical manufacturers
COVID-19 response legislation
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2024 · third_quarter · Q3
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2024 · third_quarter · Q3
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2024 · second_quarter · Q2
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2024 · second_quarter · Q2
COVID-19 response legislation
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Support for non-profit pharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2024 · second_quarter · 2T
Support for non-profit pharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2024 · second_quarter · Q2
Support for non-profit pharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2024 · second_quarter · Q2
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2024 · second_quarter · Q2
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2024 · first_quarter · Q1
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2024 · first_quarter · Q1
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Support for non-profit pharmaceutical manufacturers
COVID-19 response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2024 · first_quarter · Q1
Support for non-profit pharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2024 · first_quarter · Q1
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2024 · first_quarter · Q1
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2023 · fourth_quarter · Q4
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2023 · fourth_quarter · Q4
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2023 · fourth_quarter · Q4
Support for non-profit pharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2023 · fourth_quarter · Q4
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Support for non-profit pharmaceutical manufacturers
COVID-19 response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA ASSOCIATION OF PUBLIC HOSPITALS AND HEALTH SYSTEMS via WAXMAN STRATEGIES
2023 · fourth_quarter · Q4
Issues related to Medicaid DSH payments
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2023 · fourth_quarter · Q4
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA ASSOCIATION OF PUBLIC HOSPITALS AND HEALTH SYSTEMS via WAXMAN STRATEGIES
2023 · third_quarter · Q3
Issues related to Medicaid DSH payments
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2023 · third_quarter · Q3
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2023 · third_quarter · Q3
COVID-19 response legislation
Support for non-profit pharmaceutical manufacturers
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2023 · third_quarter · Q3
Support for non-profit pharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2023 · third_quarter · Q3
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2023 · third_quarter · Q3
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2023 · second_quarter · Q2
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2023 · second_quarter · Q2
Support for non-profit pharmaceutical manufacturers
COVID-19 response legislation
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2023 · second_quarter · Q2
Support for non-profit pharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2023 · second_quarter · Q2
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2023 · second_quarter · Q2
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA ASSOCIATION OF PUBLIC HOSPITALS AND HEALTH SYSTEMS via WAXMAN STRATEGIES
2023 · first_quarter · 1T
Issues related to Medicaid DSH payments
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2023 · first_quarter · Q1
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2023 · first_quarter · Q1
Support for non-profit pharmaceutical manufacturers
COVID-19 response legislation
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2023 · first_quarter · Q1
Support for non-profit pharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2023 · first_quarter · Q1
Issues impacting drug prices and health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2023 · first_quarter · Q1
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS via WAXMAN STRATEGIES
2023 · first_quarter · 1T
COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2022 · fourth_quarter · Q4
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2022 · fourth_quarter · Q4
COVID-19 response legislation
Appropriations for the Paralysis Resource Center (PRC), Administration for Community Living (ACL), Department of Health and Human Services (HHS)
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2022 · fourth_quarter · Q4
Support for non-profit pharmaceutical manufacturers, S. 2257
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2022 · fourth_quarter · Q4
Issues impacting drug prices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA ASSOCIATION OF PUBLIC HOSPITALS AND HEALTH SYSTEMS via WAXMAN STRATEGIES
2022 · fourth_quarter · Q4
Issues related to Mediciad DSH payments
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2022 · fourth_quarter · Q4
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS via WAXMAN STRATEGIES
2022 · fourth_quarter · Q4
COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA ASSOCIATION OF PUBLIC HOSPITALS AND HEALTH SYSTEMS via WAXMAN STRATEGIES
2022 · third_quarter · Q3
Issues related to Mediciad DSH payments
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2022 · third_quarter · Q3
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2022 · third_quarter · Q3
Appropriations for the Paralysis Resource Center (PRC), Administration for Community Living (ACL), Department of Health and Human Services (HHS)
COVID-19 response legislation
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2022 · third_quarter · Q3
Support for non-profit pharmaceutical manufacturers, S. 2257
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2022 · third_quarter · Q3
Issues impacting drug prices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2022 · third_quarter · Q3
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS via WAXMAN STRATEGIES
2022 · third_quarter · Q3
COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2022 · second_quarter · Q2
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2022 · second_quarter · Q2
Appropriations for the Paralysis Resource Center (PRC), Administration for Community Living (ACL), Department of Health and Human Services (HHS)
COVID-19 response legislation
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2022 · second_quarter · Q2
Support for non-profit pharmaceutical manufacturers, S. 2257
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2022 · second_quarter · Q2
Issues impacting drug prices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA ASSOCIATION OF PUBLIC HOSPITALS AND HEALTH SYSTEMS via WAXMAN STRATEGIES
2022 · second_quarter · Q2
Issues related to Mediciad DSH payments
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2022 · second_quarter · Q2
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS via WAXMAN STRATEGIES
2022 · second_quarter · Q2
COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA ASSOCIATION OF PUBLIC HOSPITALS AND HEALTH SYSTEMS via WAXMAN STRATEGIES
2022 · first_quarter · 1A
Issues related to Mediciad DSH payments
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAMPAIGN FOR TOBACCO FREE KIDS via WAXMAN STRATEGIES
2022 · first_quarter · Q1
Issues related to tobacco, e-cigarettes and public health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHRISTOPHER AND DANA REEVE FOUNDATION via WAXMAN STRATEGIES
2022 · first_quarter · Q1
COVID-19 response legislation
Appropriations for the Paralysis Resource Center (PRC), Administration for Community Living (ACL), Department of Health and Human Services (HHS)
Provisions related to Home and Community Based Services for Medicaid - monitored inclusion in COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2022 · first_quarter · Q1
Support for non-profit pharmaceutical manufacturers, S. 2257
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2022 · first_quarter · Q1
Issues impacting drug prices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA ASSOCIATION OF PUBLIC HOSPITALS AND HEALTH SYSTEMS via WAXMAN STRATEGIES
2022 · first_quarter · Q1
Issues related to Mediciad DSH payments
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2022 · first_quarter · Q1
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS via WAXMAN STRATEGIES
2022 · first_quarter · Q1
COVID response legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE